Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. SECURES EXCLUSIVE GLOBAL LICENSE FOR AI-DRIVEN LIVER DISEASE RISK IDENTIFICATION TECHNOLOGY

Alzai Health Corp. has entered into an exclusive worldwide licence agreement with MOR Research Applications Ltd., the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. (Yeda), for proprietary artificial intelligence-driven liver disease risk identification technology (the licensed technology).

Under the agreement, Alzai is granted an exclusive, worldwide, sublicensable licence to develop, commercialize and sublicense the licensed technology. The licensed technology is intended to identify individuals at elevated risk of liver-associated diseases, including cirrhosis and other chronic liver conditions, using routine health care data.

The licensed technology is derived from proprietary algorithms and intellectual property developed by leading Israeli health care and academic institutions, and is designed to support identification of individuals who may be at risk of liver disease before clinical diagnosis. Alzai intends to integrate the licensed technology into its existing artificial intelligence platform and advance commercialization of the licensed technology through health care systems, life sciences organizations, pharmaceutical companies and strategic commercial partners worldwide.

Under the terms of the agreement, Alzai will pay customary royalties to MOR and Yeda based on future commercialization revenues generated from products derived from the licensed technology, as well as a portion of revenues received through sublicensing arrangements. The licensed technology has been licensed on an exclusive basis within the field of liver-associated diseases and includes rights for Alzai to further develop, commercialize and sublicense the licensed technology globally.

Liver disease represents one of the fastest-growing health care challenges globally. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is estimated to affect more than one-third of the global adult population, while millions of individuals remain undiagnosed until advanced stages of MASLD. Current diagnostic approaches often require specialized testing, imaging procedures or specialist referrals, creating significant barriers to large-scale population screening.

Alzai believes that artificial intelligence-driven analysis of routine health care data has the potential to support earlier identification of at-risk individuals, which may assist health care providers in prioritizing follow-up assessment, intervention and disease management.

The agreement represents a strategic expansion of Alzai's disease risk identification platform beyond Alzheimer's disease and into additional chronic disease markets. The company believes the addition of liver disease risk identification capabilities expands the company's portfolio of artificial intelligence-driven disease prediction solutions utilizing existing healthcare data.

"This agreement represents a significant milestone in Alzai's evolution from a single-disease company into a broader artificial intelligence-driven disease risk identification platform," said Hayim Raclaw, chief executive officer of Alzai Health. "Liver disease is a major global health care challenge that affects hundreds of millions of individuals worldwide and is frequently underdiagnosed until later stages of progression. By combining this innovative liver disease technology with Alzai's existing artificial intelligence infrastructure, validation expertise and commercialization strategy, we believe we can accelerate the development of scalable solutions that help health care organizations identify at-risk individuals earlier and more efficiently. This expansion aligns with our long-term vision of building a multidisease platform capable of supporting the development of risk identification tools across a range of chronic diseases."

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale healthcare data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.